Illinois General Assembly - Full Text of Public Act 094-0122
Illinois General Assembly

Previous General Assemblies

Public Act 094-0122


 

Public Act 0122 94TH GENERAL ASSEMBLY



 


 
Public Act 094-0122
 
SB0521 Enrolled LRB094 08108 LJB 38293 b

    AN ACT concerning insurance.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Insurance Code is amended by
changing Section 356u as follows:
 
    (215 ILCS 5/356u)
    Sec. 356u. Pap tests and prostate-specific antigen tests.
    (a) A group policy of accident and health insurance that
provides coverage for hospital or medical treatment or services
for illness on an expense-incurred basis and is amended,
delivered, issued, or renewed after the effective date of this
amendatory Act of 1997 shall provide coverage for all of the
following:
        (1) An annual cervical smear or Pap smear test for
    female insureds.
        (2) An annual digital rectal examination and a
    prostate-specific antigen test, for male insureds upon the
    recommendation of a physician licensed to practice
    medicine in all its branches for:
            (A) asymptomatic men age 50 and over;
            (B) African-American men age 40 and over; and
            (C) men age 40 and over with a family history of
        prostate cancer.
        (3) Surveillance tests for ovarian cancer for female
    insureds who are at risk for ovarian cancer.
    (b) This Section shall not apply to agreements, contracts,
or policies that provide coverage for a specified disease or
other limited benefit coverage.
    (c) For the purposes of this Section:
    "At risk for ovarian cancer" means:
        (1) having a family history (i) with one or more
    first-degree relatives with ovarian cancer, (ii) of
    clusters of women relatives with breast cancer, or (iii) of
    nonpolyposis colorectal cancer; or
        (2) testing positive for BRCA1 or BRCA2 mutations.
    "Surveillance tests for ovarian cancer" means annual
screening using (i) CA-125 serum tumor marker testing, (ii)
transvaginal ultrasound, (iii) pelvic examination.
(Source: P.A. 90-7, eff. 6-10-97.)
 
    Section 99. Effective date. This Act takes effect January
1, 2006.

Effective Date: 1/1/2006